(Q34634212)

3 August 2017

1 reference

title

Adherence-resistance relationships to combination HIV antiretroviral therapy (English)

1 reference

3 August 2017

0 references

anti-retroviral agent

0 references

1

David R Bangsberg

1 reference

3 August 2017

3

Steven G Deeks

1 reference

3 August 2017

Deanna L Kroetz

2

1 reference

3 August 2017

publication date

1 May 2007

1 reference

3 August 2017

published in

Current HIV/AIDS reports

1 reference

3 August 2017

volume

4

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

65-72

1 reference

https://scigraph.springernature.com/pub.10.1007/s11904-007-0010-0

3 August 2017

exact match

0 references

cites work

In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11904-007-0010-0

Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation

21 January 2018

1 reference

12 December 2020

Efavirenz intoxication due to slow hepatic metabolism

1 reference

12 December 2020

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

12 December 2020

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

1 reference

12 December 2020

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

1 reference

12 December 2020

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants

1 reference

12 December 2020

Preventing antiretroviral anarchy in sub-Saharan Africa

1 reference

12 December 2020

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy

1 reference

12 December 2020

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450

1 reference

12 December 2020

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

1 reference

12 December 2020

Selective drug taking during combination antiretroviral therapy in an unselected clinic population.

1 reference

12 December 2020

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda

1 reference

12 December 2020

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

1 reference

12 December 2020

Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs

1 reference

12 December 2020

Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants

1 reference

12 December 2020

Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study

1 reference

12 December 2020

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda

1 reference

12 December 2020

Update of the drug resistance mutations in HIV-1: Fall 2006.

1 reference

12 December 2020

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

1 reference

12 December 2020

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

12 December 2020

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

1 reference

12 December 2020

Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent

1 reference

12 December 2020

Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients

1 reference

12 December 2020

Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring

1 reference

12 December 2020

1 reference

12 December 2020

Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis

1 reference

12 December 2020

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

12 December 2020

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

12 December 2020

Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir

1 reference

12 December 2020

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen

1 reference

12 December 2020

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study

1 reference

12 December 2020

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

12 December 2020

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

1 reference

12 December 2020

Is average adherence to HIV antiretroviral therapy enough?

1 reference

12 December 2020

Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo

1 reference

12 December 2020

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance

1 reference

12 December 2020

Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy

1 reference

12 December 2020

Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

1 reference

12 December 2020

An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children

1 reference

12 December 2020

Treatment of antiretroviral-drug-resistant HIV-1 infection

1 reference

12 December 2020

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

1 reference

12 December 2020

Protease inhibitors in the homeless

1 reference

12 December 2020

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

1 reference

12 December 2020

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

1 reference

12 December 2020

Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

1 reference

12 December 2020

Doctors withhold H.I.V. pill regimen from some

1 reference

12 December 2020

Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro

1 reference

12 December 2020

Antiretroviral therapy in Africa

1 reference

12 December 2020

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs

1 reference

12 December 2020

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

1 reference

12 December 2020

First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world

1 reference

12 December 2020

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy

1 reference

12 December 2020

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen

1 reference

12 December 2020

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

1 reference

12 December 2020

1 reference

12 December 2020

Attaining higher goals in HIV treatment: the central importance of adherence

1 reference

12 December 2020

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity

1 reference

12 December 2020

The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone

1 reference

12 December 2020

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

1 reference

12 December 2020

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

1 reference

12 December 2020

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

12 December 2020

Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1

1 reference

12 December 2020

Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression

1 reference

12 December 2020

Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation

1 reference

12 December 2020

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection

1 reference

12 December 2020

Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance

1 reference

12 December 2020

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

12 December 2020

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

1 reference

12 December 2020

The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials

1 reference

12 December 2020

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

1 reference

12 December 2020

The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities

1 reference

12 December 2020

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy

1 reference

12 December 2020

Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators

1 reference

12 December 2020

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

12 December 2020

The era of adherence to HIV therapy

1 reference

12 December 2020

Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).

1 reference

12 December 2020

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

1 reference

12 December 2020

10.1007/S11904-007-0010-0

Identifiers

DOI

1 reference

3 August 2017

1 reference